News
UNICOS Launches V-Flash Eyeliner Stamp, Bringing One-Press Winged Liner to Busy Beauty Routines
1+ hour, 2+ min ago (482+ words) NEW YORK, Feb. 21, 2026 (GLOBE NEWSWIRE) -- UNICOS Beauty has launched the V-Flash Eyeliner Stamp, a new makeup tool designed to simplify one of beauty's most time-consuming steps: winged eyeliner. Featuring a patented pressing mechanism, the product delivers a clean, symmetrical wing…...
Non-Narcotic Analgesics Allergy Labels Linked to Adverse Maternal and Fetal Outcomes
2+ hour, 23+ min ago (191+ words) Increased rates of NICU admission, preterm birth, eclampsia and additional adverse outcomes were shown for mothers with this allergy label and their infants MILWAUKEE, Feb. 21, 2026 /PRNewswire/ -- A non-narcotic analgesics allergy label (NNAAL) is associated with several adverse perinatal outcomes, indicating…...
DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy
2+ week, 4+ day ago (1405+ words) If approved, DATROWAY could become the standard of care in this setting DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca. The sBLA…...
Launching a Think Tank to Advance Maternal Vitality in Georgia
3+ week, 1+ day ago (305+ words) The Maternal Health Vitality Think Tank unites cross-sector leaders to transform care, strengthen workforce, and align resources ATLANTA, Jan. 29, 2026 /PRNewswire/ -- A statewide collaborative of health care providers, public health leaders, researchers, philanthropy, and community-based organizations announce the launch of a…...
BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients
3+ week, 4+ day ago (233+ words) 9 of 25 BriaCell patients treated since 2022remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard of care therapies in similar patient populations Bria-IMT regimen continues under Fast Track Designation from US FDA Table 1: Ongoing Long-Term Survivors Months Since Study Start…...
ProgenyHealth Releases 2026 Maternal & Infant Health Trends Report
1+ mon, 14+ hour ago (355+ words) Report identifies 5 emerging trends within maternal and infant health and'what they reveal about the state of the industry now and for the future America has a maternal and infant health emergency. With the highest maternal mortality'rate among the world's high-income…...
Feminist Leaders United for a "State of Feminism" Salon at Gloria Steinem's Home
1+ mon, 4+ week ago (279+ words) A cross-generational gathering explores the future of feminist strategy, narrative power, and the evolution of feminist media. The salon echoed'Feminist.com's first State of Feminism convening at'Steinem's home in 2012, revisiting that intergenerational moment while aligning with the tradition of Talking…...
BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer
2+ mon, 4+ day ago (168+ words) The clinical study demonstrated that BioVaxys' MVP-S in combination with letrozole (a commonly used neoadjuvant hormone therapy for treating some types of breast cancer by decreasing the amount of estrogen hormone your body makes) generated a strong immune response in…...
Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer
2+ mon, 1+ week ago (189+ words) Breast cancer is the most common cancer in women worldwide, with approximately 2.3 million new cases diagnosed in 2022.1 Despite advances in treatment, recurrence remains a key concern for patients with HR+/HER2- disease, which represents roughly 70% of all breast cancer cases.2 Funded…...
SABCS 2025: REVEAL GENOMICS Presents Major Advance in Predicting Brain Metastasis in HER2+ Breast Cancer
2+ mon, 1+ week ago (497+ words) The new HER2DX central nervous system (CNS) progression score predicts risk of brain progression in advanced HER2+ breast cancer, addressing a major unmet need in identifying patients at the highest risk of CNS involvement. During SABCS 2025, the company presents a total of…...